EGFR Genetic Alteration Cell Panel (ATCC® TCP-1027)

Organism: Homo sapiens, human  / 

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Components ATCC CRL-2868 HCC827
ATCC CRL-2871 HCC4006
ATCC CRL-5908 NCI-H1975
ATCC CRL-5928 NCI-H2170
ATCC HTB-20 BT-474
Applications This panel is useful for EGFR pathway research and for anti-cancer drug discovery.
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Comments EGFR/ERBB1/HER1 and ERBB2/EGFR2/HER2 are members of the ErbB super family of receptor tyrosine kinases. These receptors bind multiple EGF family-member ligands to initiate signaling cascades critical for an array of cellular processes, such as proliferation, differentiation, survival, metabolism, and migration. EGFR and ERBB2 are targets of an expanding class of anticancer therapies. The most common mutations associated with sensitivity to EGFR inhibitors include exon 19 deletions and the L858R point mutation.  Conversely, the EGFR T790M Mutation has been linked to drug resistance.  

The EGFR genetic alteration cell panel (ATCC TCP-1027) is composed of eleven human tumor cell lines from various common cancer types that carry hotspot mutations or gene copy number amplification within the EGFR or ERBB2 gene. The EGFR and ERBB2 status of each cell line has been sequenced and validated by ATCC. This panel is useful for EGFR pathway research and for anti-cancer drug discovery.

Product Format frozen
Storage Conditions LN vapor (less than -130°C) only
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • For-profit customers must obtain a research use license agreement from the Contributor prior to shipment.
  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:

  1. The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose;
  2. Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and
  3. Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity.

The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above.

For instructions on how to obtain a license from Institution, please contact John B. Scott, Ph.D. at the Institution Office of Technology Commercialization via email at